IMVT
Immunovant Inc.
$22.59
-$0.20(-0.88%)
58
Overall
50
Value
66
Tech
--
Quality
Market Cap
$4.15B
Volume
1.89M
52W Range
$12.72 - $29.49
Target Price
$38.73
Company Overview
| Mkt Cap | $4.15B | Price | $22.59 |
| Volume | 1.89M | Change | -0.88% |
| P/E Ratio | -10.0 | Open | $22.20 |
| Revenue | -- | Prev Close | $22.79 |
| Net Income | $-413.8M | 52W Range | $12.72 - $29.49 |
| Div Yield | N/A | Target | $38.73 |
| Overall | 58 | Value | 50 |
| Quality | -- | Technical | 66 |
No chart data available
About Immunovant Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Latest News
H.C. Wainwright Reaffirms Their Buy Rating on Immunovant (IMVT)
TipRanks Auto-Generated Intelligence Newsdesk•9 days ago
Oppenheimer Sticks to Its Buy Rating for Immunovant (IMVT)
TipRanks Auto-Generated Intelligence Newsdesk•12 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMVT | $22.59 | -0.9% | 1.89M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |